|Articles|March 1, 2004

No user fee needed for extina

Connetics Corp. has received notifications from the FDA that no user fee is required for the new drug application seeking marketing clearance for Extina (ketoconazole 2 percent) Foam. Previously, Connects announced positive results from its Phase III clinical trial with Extina versus Nizoral.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME